[Primary Sjögren's syndrome and glomerulonephritis].
METHODS
An 82-year-old woman with hypertension for 20 years developed a nephrotic syndrome with severe oedema followed by acute oliguric renal failure after a bout of bronchitis and a gastrointestinal infection. She also complained of xerostomia and dry eyes of recent onset.


METHODS
Biochemical tests showed a serum creatinine level of 6.1 mg/dl, a 1:5120 antinuclear antibody (ANA) titre, and positive values for Ro(SS-A) and La(SS-B) antibodies. HLA-DR typing demonstrated HLA-DR3 (HLA-DRB1*0301) and DR13 (HLA-DRB1*13) antigens. Renal biopsy revealed minimal glomerular lesions with focal and segmental glomerulo-sclerosis as well as (hypertension-induced) benign nephrosclerosis and focal tubular atrophy with interstitial fibrosis.


METHODS
After two hemofiltrations and concomitant administration of 100 mg prednisone renal function quickly improved and the proteinuria fell to 1 g/dl. At the same time the xerostomia improved. The nephrotic syndrome recurred 7 months later after the prednisone dose had been reduced to 10 mg/d, but after the dose had been raised to 50 mg/d and cyclosporin A (150 mg/d) had been added a lasting remission occurred and renal function became stable though impaired.


CONCLUSIONS
The relatively rare association of glomerular disease (here focal segmental glomerulosclerosis) with Sjögren's syndrome can, as in this case, be triggered by a viral infection. A genetic predisposition for Sjögren's syndrome is suggested by the demonstration of HLA-DR3 alleles. Administration of steroids is indicated for the treatment of the nephrotic syndrome and, in case of recurrence, can be combined with cyclosporin A. Both drugs also influence the symptoms of Sjögren's syndrome.
Tholl
U
U
Medizinische Klinik II, Zentralkrankenhaus Reinkenheide, Bremerhaven.
Hartung
K
K
Helmchen
U
U
Anlauf
M
M
D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications* / Q000628:therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D015803:HLA-DR3 Antigen / Q000032:analysis; D006440:Hemofiltration; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology / Q000648:ultrastructure; D009404:Nephrotic Syndrome / Q000150:complications* / Q000628:therapy; D011239:Prednisolone / Q000627:therapeutic use; D012859:Sjogren's Syndrome / Q000150:complications* / Q000235:genetics / Q000628:therapy
D005938:Glucocorticoids; D015803:HLA-DR3 Antigen; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone